| 產(chǎn)品編號(hào) | bs-0182R-Gold |
| 英文名稱1 | Rabbit Anti-PTP1B/Gold Conjugated antibody |
| 中文名稱 | 膠體金標(biāo)記的蛋白酪氨酸磷酸酶-1B抗體 |
| 別 名 | PTP-1B; Non receptor tyrosine phosphatase 1; Protein tyrosine phosphatase 1B; Protein-tyrosine phosphatase 1B; Protein tyrosine phosphatase non receptor type 1; Protein tyrosine phosphatase placental; PTP 1B; PTPN 1; PTPN1; Tyrosine protein phosphatase non receptor type 1; PTP-HA2; Protein-tyrosine phosphatase HA2; PTN1_HUMAN. |
| 規(guī)格價(jià)格 | 100ul/2980元 購(gòu)買 大包裝/詢價(jià) |
| 說 明 書 | 100ul（10nm 15nm 35nm） |
| 研究領(lǐng)域 | 細(xì)胞生物 神經(jīng)生物學(xué) 信號(hào)轉(zhuǎn)導(dǎo) 激酶和磷酸酶 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | Human, (predicted: Mouse, Rat, Pig, Cow, Horse, Rabbit, ) |
| 產(chǎn)品應(yīng)用 | IEM=1:20-200 ICA=1:20-200 ChIP=1:20-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 48kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 0.4mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human PTP-1B C-terminus |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲(chǔ) 存 液 | 0.02M TBS(pH8.2) with 1% BSA, 0.03% Proclin300. |
| 保存條件 | Store at 2-8 oC for 3-6 months. Avoid repeated freeze/thaw cycles. |
| 產(chǎn)品介紹 |
background: PTP1B is the prototypic member of the protein tyrosine phosphatase (PTP) family, which comprises at least 37 proteins. The family is characterized by a catalytic phosphatase domain of approximately 240 amino acids, and includes both transmembrane and cytosolic enzymes. The PTPs have high substrate specificity for phosphotyrosyl proteins. At the primary sequence level, PTPs share little similarity with the protein serine phosphatases, protein threonine phosphatases, or the acid and alkaline phosphatases. PTP1B is a negative regulator of insulin and leptin signal transduction and is a drug discovery target in the fields of diabetes and obesity. Insulin also influences the expression of splice variants of PTP1B. PTP1B also interacts with Insulin and EGF receptors, and undergoes phosphorylation after receptor stimulation. Tyrosine phosphorylation at Tyr-66, Tyr-152, and Tyr-153 occurs after insulin receptor activation, and tyrosine phosphorylation of Tyr-152 may be required for interactions with N-Cadherin. In addition, Akt can phosphorylate Ser-50 and this phosphorylation can reduce PTP1B activity. Function: Tyrosine-protein phosphatase which acts as a regulator of endoplasmic reticulum unfolded protein response. Mediates dephosphorylation of EIF2AK3/PERK; inactivating the protein kinase activity of EIF2AK3/PERK. May play an important role in CKII- and p60c-src-induced signal transduction cascades. May regulate the EFNA5-EPHA3 signaling pathway which modulates cell reorganization and cell-cell repulsion Subunit: Interacts with EPHA3 (phosphorylated); dephosphorylates EPHA3 and may regulate its trafficking and function. Subcellular Location: Endoplasmic reticulum membrane; Peripheral membrane protein; Cytoplasmic side. Note=Interacts with EPHA3 at the cell membrane. Tissue Specificity: Most abundant in testis. Also found in kidney, spleen, muscle, liver, heart and brain. Post-translational modifications: Ser-50 is the major site of phosphorylation as compared to Ser-242 and Ser-243. Activated by phosphorylation at Ser-50. S-nitrosylation of Cys-215 inactivates the enzyme activity. Sulfhydration at Cys-215 following endoplasmic reticulum stress inactivates the enzyme activity, promoting EIF2AK3/PERK activity. Database links: Entrez Gene: 5770 Human Entrez Gene: 19246 Mouse Omim: 176885 Human SwissProt: P18031 Human SwissProt: P35821 Mouse Unigene: 417549 Human Unigene: 277916 Mouse Unigene: 11317 Rat Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 蛋白酪氨酸磷酸酶1B（PTP1B）是一種胰島素信號(hào)的負(fù)性調(diào)節(jié)因子，與肥胖癥和2型糖尿病的發(fā)病及發(fā)展關(guān)系密切。對(duì)P-tyr基因敲除小鼠的研究表明，缺失PTP1B小鼠的胰島素敏感性明顯增加，并對(duì)肥胖有一定的抵抗作用，而另一些對(duì)動(dòng)物和人體的研究結(jié)果卻與此相反，發(fā)現(xiàn)PTP1B可通過引起胰島素抵抗、瘦素抵抗及影響脂代謝等而導(dǎo)致肥胖癥和2型糖尿病的發(fā)生。一些特異性的Ptyr小分子抑制劑已經(jīng)開發(fā)并用于肥胖和糖尿病的治療中。 |
